Recombinant SARS-CoV-2 (COVID-19) S Antilichaam [2B7]

The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS) . The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

43740568

QHD43416

QHD43416

Virus

Full length recombinant S Protein

2B7

Unconjugated

Primary Antibodies

Infectious Disease, COVID-19

≥95 %

5.0 mg/ml (+/- 10 %)

PBS, pH 7.4

None

Blue Ice

24 months from manufacturing at <-20 &#730; C; 1 month, 2 to 8 &#730; C under sterile conditions.

Human IgG1

Antibody recognizes 2019-nCoV S-NTD Protein.

Immunoreactivity: 80–120 % compared to the reference sample in an ELISA test.

S

Surface glycoprotein

Severe acute respiratory syndrome coronavirus 2

SARS-CoV-2 (COVID-19) Spike S1 Antibody: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Surface Glycoprotein, Spike protein

ELISA

1791269090

Liquid